0000000001190073

AUTHOR

D Wang

showing 3 related works from this author

Safety of hospital discharge before return of bowel function after elective colorectal surgery

2020

Ileus is common after colorectal surgery and is associated with an increased risk of postoperative complications. Identifying features of normal bowel recovery and the appropriateness for hospital discharge is challenging. This study explored the safety of hospital discharge before the return of bowel function.A prospective, multicentre cohort study was undertaken across an international collaborative network. Adult patients undergoing elective colorectal resection between January and April 2018 were included. The main outcome of interest was readmission to hospital within 30 days of surgery. The impact of discharge timing according to the return of bowel function was explored using multiva…

operativeMalepostoperative dischargePostoperative Complications0302 clinical medicineColostomyCRITERIAProspective StudiesBowel functionColectomyIMAGINEstomaintestinesProctectomyIleostomydigestive oral and skin physiologypatient dischargecolorectal surgery hospital discharge bowel functionRECOVERYMiddle Agedadult; colostomy; elective surgical procedures; female; follow-up studies; humans; ileostomy; ileus; male; middle aged; multivariate analysis; patient discharge; patient readmission; patient safety; postoperative complications; prospective studies; recovery of function; colectomy; proctectomyPatient DischargeColorectal surgeryileus - - discharge - bowel function - elective - colorectal surgeryElective Surgical Procedures030220 oncology & carcinogenesisFemale030211 gastroenterology & hepatologyPatient SafetyCohort studysafetyAdultmedicine.medical_specialtyIleusPatient Readmissiondefecation03 medical and health sciencesIleuspostoperative complicationsmedicineHospital dischargeHumanscolorectal surgery; postoperative discharge; IMAGINE; stomacolorectal resectionColorectal resectiondefecation postoperative complications colorectal surgery intestines patient discharge patient readmission safety surgical procedures operative colorectal resection ileusbusiness.industryRecovery of FunctionOdds ratiomedicine.diseasedigestive system diseasessurgical proceduresSurgeryMultivariate AnalysisDefecationcolorectal surgerySurgerybusinessFollow-Up Studies
researchProduct

Two-particle transverse momentum correlations in pp and p-Pb collisions at energies available at the CERN Large Hadron Collider

2023

Two-particle transverse momentum differential correlators, recently measured in Pb--Pb collisions at energies available at the CERN Large Hadron Collider (LHC), provide an additional tool to gain insights into particle production mechanisms and infer transport properties, such as the ratio of shear viscosity to entropy density, of the medium created in Pb-Pb collisions. The longitudinal long-range correlations and the large azimuthal anisotropy measured at low transverse momenta in small collision systems, namely pp and p-Pb, at LHC energies resemble manifestations of collective behaviour. This suggests that locally equilibrated matter may be produced in these small collision systems, simil…

two particle correlations large hadron colliderCERN Lablongitudinallarge hadron colliderheavy ion scatteringcollectiveFOS: Physical sciencesanisotropy measuredtransverse momentum correlation[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]High Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)transport theoryTeVcorrelation functionNuclear Experiment (nucl-ex)Nuclear ExperimentMonte Carloeffect viscositycorrelation long-rangetwo-particleentropy densityparticle multiplicityCERN LHC Collangular distribution anisotropybroadeningtransverse momentum lowydinfysiikkatwo particle correlations
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct